Abstract：
BACKGROUND: Recently, some evidence emphasized the value of MSH2 and MSH6 inactivation and their hypermutation in predicting different cancers. The present consideration is to evaluate the value of MSH2 and MSH6 protein deficient studied by the immunohistochemistry (IHC) method and the tumor behaviors and aggressiveness in prostatic carcinoma.
METHODS: This cross-sectional study was performed on 80 examples extricated from patients who endured prostate cancer and were planned for radical prostatectomy surgery. The expression levels of the genes were studied by IHC staining.
RESULTS: The deficiency in MSH2 and MSH6 expression was revealed in 10.0 % and 11.3 % of patients respectively, while the reduction of simultaneous expression in two genes was found in 6.2 % of patients. In the two subgroups with and without MSH2 and/or MSH6 staining, there was no difference in patients\' mean age and history of prostate cancer. There was also no difference in tumor-related behaviors including combined Gleason grade group, tumor stage, vascular invasion, perineural invasion, and prostatic capsular invasion between the groups with and without gene loss.
CONCLUSIONS: The evaluation of the deficient rate of two genes among patients with prostate cancer to predict the tumor grade and its aggressive behavior needs further study in every population.
METHODS: This cross-sectional study was performed on 80 examples extricated from patients who endured prostate cancer and were planned for radical prostatectomy surgery. The expression levels of the genes were studied by IHC staining.
RESULTS: The deficiency in MSH2 and MSH6 expression was revealed in 10.0 % and 11.3 % of patients respectively, while the reduction of simultaneous expression in two genes was found in 6.2 % of patients. In the two subgroups with and without MSH2 and/or MSH6 staining, there was no difference in patients\' mean age and history of prostate cancer. There was also no difference in tumor-related behaviors including combined Gleason grade group, tumor stage, vascular invasion, perineural invasion, and prostatic capsular invasion between the groups with and without gene loss.
CONCLUSIONS: The evaluation of the deficient rate of two genes among patients with prostate cancer to predict the tumor grade and its aggressive behavior needs further study in every population.
摘要：
背景：最近，一些证据强调了MSH2和MSH6失活及其超突变在预测不同癌症中的价值。目前的考虑是评估通过免疫组织化学（IHC）方法研究的MSH2和MSH6蛋白缺陷的价值以及前列腺癌的肿瘤行为和侵袭性。
方法：这项横断面研究是对80例患者进行的，这些患者患有前列腺癌并计划进行根治性前列腺切除术。通过IHC染色研究基因的表达水平。
结果：在10.0%和11.3%的患者中发现MSH2和MSH6表达不足，而在6.2％的患者中发现两个基因的同时表达减少。在有和没有MSH2和/或MSH6染色的两个亚组中，患者的平均年龄和前列腺癌病史没有差异.合并Gleason分级组的肿瘤相关行为也没有差异，肿瘤分期,血管浸润,神经周浸润,以及有基因缺失和无基因缺失组之间的前列腺包膜侵袭。
结论：评估前列腺癌患者中两个基因的缺失率，以预测肿瘤分级及其侵袭行为，需要在每个人群中进一步研究。
方法：这项横断面研究是对80例患者进行的，这些患者患有前列腺癌并计划进行根治性前列腺切除术。通过IHC染色研究基因的表达水平。
结果：在10.0%和11.3%的患者中发现MSH2和MSH6表达不足，而在6.2％的患者中发现两个基因的同时表达减少。在有和没有MSH2和/或MSH6染色的两个亚组中，患者的平均年龄和前列腺癌病史没有差异.合并Gleason分级组的肿瘤相关行为也没有差异，肿瘤分期,血管浸润,神经周浸润,以及有基因缺失和无基因缺失组之间的前列腺包膜侵袭。
结论：评估前列腺癌患者中两个基因的缺失率，以预测肿瘤分级及其侵袭行为，需要在每个人群中进一步研究。
